{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:25:32Z","timestamp":1763727932552,"version":"build-2065373602"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.pathol.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T17:14:27Z","timestamp":1615223667000},"page":"427-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of new myeloma agents on the transfusion laboratory"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0791","authenticated-orcid":false,"given":"Andrew D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-4997","authenticated-orcid":false,"given":"Morvarid","family":"Moayeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-4431","authenticated-orcid":false,"given":"Ashok","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.01.001_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"7","author":"Shepard","year":"2017","journal-title":"Clin Med Lond Engl"},{"key":"10.1016\/j.pathol.2021.01.001_bib2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2021.01.001_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pathol.2021.01.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.pathol.2021.01.001_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"10.1016\/j.pathol.2021.01.001_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S49480","article-title":"Potential role of daratumumab in the treatment of multiple myeloma","volume":"7","author":"Mark","year":"2014","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.pathol.2021.01.001_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.01.001_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"year":"2020","series-title":"FDA approves isatuximab-irfc for multiple myeloma","author":"US Food and Drug Administration","key":"10.1016\/j.pathol.2021.01.001_bib11"},{"year":"2020","series-title":"SARCLISA (isatuximab-irfc) injection prescribing information","author":"Sanofi-Aventis US LLC","key":"10.1016\/j.pathol.2021.01.001_bib12"},{"key":"10.1016\/j.pathol.2021.01.001_bib13","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2021.01.001_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.pathol.2021.01.001_bib15","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1\u20132a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pathol.2021.01.001_bib16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy: transfusion complicated due to MoAb therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.hoc.2019.05.007","article-title":"Impact of novel monoclonal antibody therapeutics on blood bank pretransfusion testing","volume":"33","author":"Mei","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.pathol.2021.01.001_bib18","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib19","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib20","first-page":"28A","article-title":"Myeloma patients receiving daratumumab (anti-CD38) can appear to have an antibody with Lutheran-related specificity","volume":"55","author":"Aye","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib21","first-page":"26A","article-title":"Daratumumab-derived anti-CD38 can be easily mistaken for clinically significant antibodies to Lutheran antigens or to Knops antigens","volume":"55","author":"Velliquette","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/0973-6247.214358","article-title":"Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody","volume":"11","author":"Lin","year":"2017","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.pathol.2021.01.001_bib23","first-page":"142A","article-title":"Serologic findings in patients treated with daratumumab \u2013 experience of a transfusion service","volume":"56","author":"Bakhtary","year":"2016","journal-title":"Transfusion"},{"year":"2016","series-title":"Mitigating the anti-CD38 interference with serologic testing","author":"Regan","key":"10.1016\/j.pathol.2021.01.001_bib24"},{"key":"10.1016\/j.pathol.2021.01.001_bib25","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/trf.13267","article-title":"Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma: letters to the editor","volume":"55","author":"Hannon","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib26","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/trf.13174","article-title":"An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab: letters to the editor","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib27","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.01.001_bib28","first-page":"51A","article-title":"Monoclonal anti-CD38 and anti-CD47 therapy interference with platelet antibody screen test methods (IGT5-TU2-12)","volume":"58","author":"Velliquette","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib29","first-page":"117A","article-title":"Reactive platelet crossmatch results in the absence of HLA antibodies: a patient case series","volume":"56","author":"Jacquot","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0014-5793(95)00715-L","article-title":"Structural role of disulfide bridges in the cyclic ADP-ribose related bifunctional ectoenzyme CD38","volume":"368","author":"Guida","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pathol.2021.01.001_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.transci.2018.12.019","article-title":"Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals","volume":"58","author":"Youssef","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.pathol.2021.01.001_bib32","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2021.01.001_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21307\/immunohematology-2019-262","article-title":"Unexplained agglutination of stored red blood cells in Alsever\u2019s solution caused by the gram-negative bacterium Serratia liquefaciens","volume":"24","author":"Martincic","year":"2008","journal-title":"Immunohematology"},{"key":"10.1016\/j.pathol.2021.01.001_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21307\/immunohematology-2019-015","article-title":"Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab","volume":"33","author":"Disbro","year":"2017","journal-title":"Immunohematology"},{"key":"10.1016\/j.pathol.2021.01.001_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bjhh.2017.09.003","article-title":"Transfusion management for patients taking an anti-CD38 monoclonal antibody","volume":"40","author":"Bub","year":"2018","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.pathol.2021.01.001_bib36","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/trf.14244","article-title":"An evaluation of storage time for dithiothreitol-treated reagent cells: letters to the Editor","volume":"57","author":"Hugan","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/vox.12645","article-title":"Extending shelf life of dithiothreitol-treated panel RBCs to 28 days","volume":"113","author":"Sigle","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.pathol.2021.01.001_bib38","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.transci.2019.09.011","article-title":"Transfusion management in multiple myeloma patients receiving daratumumab: experience of a single tertiary care centre","volume":"59","author":"Solves","year":"2020","journal-title":"Transfus Apher Sci"},{"year":"2012","series-title":"The Blood Group Antigen Factsbook","author":"Reid","key":"10.1016\/j.pathol.2021.01.001_bib39"},{"key":"10.1016\/j.pathol.2021.01.001_bib40","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1111\/trf.14900","article-title":"Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol\/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)","volume":"58","author":"Hosokawa","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib41","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/trf.15305","article-title":"Additional validation of Osaka method (0.01 mol\/L dithiothreitol) for negating the daratumumab interference","volume":"59","author":"Hosokawa","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib42","first-page":"3056","article-title":"Probing ligand-induced conformational changes of human CD38: ligand-induced conformational change of CD38","volume":"267","author":"Berthelier","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pathol.2021.01.001_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/tme.12508","article-title":"Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies: interference of anti-CD38 monoclonal antibodies in blood bank tests","volume":"29","author":"Carre\u00f1o-Tarragona","year":"2019","journal-title":"Transfus Med"},{"key":"10.1016\/j.pathol.2021.01.001_bib44","first-page":"135A","article-title":"Validation of a trypsin-based method to resolve the interference of daratumumab","volume":"59","author":"Ibeh","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib45","first-page":"196A","article-title":"Testing samples from patients receiving anti-CD38 therapy with commercial papain treated reagent red cells","volume":"58","author":"Velliquette","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib46","first-page":"195","article-title":"A\u00a0novel adjunct automated blood bank method to manage interference from the monoclonal anti-CD38 drug daratumumab","volume":"112","author":"Mann","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.pathol.2021.01.001_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1804751","article-title":"F(ab\u2032)2 fragments to overcome daratumumab interference in transfusion tests","volume":"379","author":"Selleng","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.01.001_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000495773","article-title":"Daratumumab interference in pretransfusion testing is overcome by addition of daratumumab Fab fragments to patients\u2019 plasma","volume":"46","author":"Werle","year":"2019","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.pathol.2021.01.001_bib49","first-page":"CP257","article-title":"Use of a cord blood panel for daratumumab treated multiple myeloma patients in a clinical setting","volume":"57","author":"Barry","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib50","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/trf.14144","article-title":"How do I work up pretransfusion samples containing anti-CD38?: how I resolve anti-CD38 interference","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib51","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.pathol.2021.01.001_bib52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.pathol.2021.01.001_bib53","first-page":"80","article-title":"Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRP\u03b1 structure\u2013function","volume":"3","author":"Jalil","year":"2020","journal-title":"Antib Ther"},{"key":"10.1016\/j.pathol.2021.01.001_bib54","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.01.001_bib55","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/cas.13663","article-title":"CD47-signal regulatory protein \u03b1 signaling system and its application to cancer immunotherapy","volume":"109","author":"Murata","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pathol.2021.01.001_bib56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.pathol.2021.01.001_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13402-019-00469-5","article-title":"CD47: role in the immune system and application to cancer therapy","volume":"43","author":"Hayat","year":"2020","journal-title":"Cell Oncol"},{"key":"10.1016\/j.pathol.2021.01.001_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000342537","article-title":"Role of CD47 and signal regulatory protein alpha (SIRP\u03b1) in regulating the clearance of viable or aged blood cells","volume":"39","author":"Per-Arne","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.pathol.2021.01.001_bib59","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pathol.2021.01.001_bib60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/beha.1999.0047","article-title":"RH blood group system and molecular basis of Rh-deficiency","volume":"12","author":"Cartron","year":"1999","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.pathol.2021.01.001_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.pathol.2021.01.001_bib62","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"author":"ClinicalTrials.gov","key":"10.1016\/j.pathol.2021.01.001_bib63"},{"author":"ClinicalTrials.gov","key":"10.1016\/j.pathol.2021.01.001_bib64"},{"author":"ClinicalTrials.gov","key":"10.1016\/j.pathol.2021.01.001_bib65"},{"author":"ClinicalTrials.gov","key":"10.1016\/j.pathol.2021.01.001_bib66"},{"key":"10.1016\/j.pathol.2021.01.001_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/trf.16009","article-title":"Assessing and mitigating the interference of ALX148, a novel CD47- blocking agent, in pretransfusion compatibility testing","author":"Kim","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib68","first-page":"159A","article-title":"Serological interference in patients receiving SRF231 anti-CD47 immunotherapy (P-IG-37)","volume":"60","author":"Velliquette","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2021.01.001_bib70","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.01.001_bib71","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood.V128.22.1812.1812","article-title":"A\u00a0phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.01.001_bib72","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib73","first-page":"159A","article-title":"Serological observations in patients receiving Hu5F9-G4 monoclonal anti-CD47 therapy (CP246)","volume":"57","author":"Velliquette","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib74","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/trf.15033","article-title":"Monoclonal anti-CD47 interference in red cell and platelet testing","volume":"59","author":"Velliquette","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib75","article-title":"A\u00a0novel use of human platelet concentrate to resolve interference of anti-CD47 in serologic testing (IGT46)","volume":"58","author":"Troughton","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib76","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/blood-2018-99-118456","article-title":"Therapeutic potential of AO-176, a next generation humanized CD47 antibody, for hematologic malignancies","volume":"132","author":"Wilson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.01.001_bib77","first-page":"A147","article-title":"AO-176, a next-generation anti-CD47 antibody, induces immunogenic cell death","volume":"7","author":"Pereira","year":"2019","journal-title":"Maint Immune Balance Eff Target Immune Ther"},{"issue":"Suppl","key":"10.1016\/j.pathol.2021.01.001_bib79","article-title":"AO-176, a normal cell sparing humanized anti-CD47 antibody","volume":"13","author":"Chakraborty","year":"2019","journal-title":"Arch Oncology"},{"key":"10.1016\/j.pathol.2021.01.001_bib80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pathol.2021.01.001_bib81","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.01.001_bib82","first-page":"136A","article-title":"First experience with CD47 blocker ALX148 interference in pretransfusion testing (P-IM-56)","volume":"59","author":"Er","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib83","first-page":"191A","article-title":"Use of novel recombinant protein to overcome serologic interference by ALX148 CD47 blocker (P-NI-22)","volume":"60","author":"Aye","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2017.09.002","article-title":"Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma","volume":"18","author":"Chari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2021.01.001_bib85","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma: daratumumab and the transfusion laboratory","volume":"48","author":"Quach","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.pathol.2021.01.001_bib86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MOH.0000000000000276","article-title":"New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing","volume":"23","author":"De Vooght","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pathol.2021.01.001_bib87","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/trf.13474","article-title":"Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing: letters to the editor","volume":"56","author":"De Vooght","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib88","first-page":"216A","article-title":"Assessment of the impact of daratumumab on a transfusion service","volume":"56","author":"Bakhtary","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib89","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/trf.15134","article-title":"The impact of daratumumab on transfusion service costs: daratumumab costs","volume":"59","author":"Cushing","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib90","first-page":"261A","article-title":"Management of anti-CD38 interference at a large academic medical center","volume":"56","author":"Thomas","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib91","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","article-title":"Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review","volume":"4","author":"Migdady","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2021.01.001_bib92","first-page":"317","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.pathol.2021.01.001_bib93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pathol.2021.01.001_bib94","first-page":"197A","article-title":"Automated electronic notification of medications report enhances transfusion safety","volume":"59","author":"Moayeri","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib95","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMc1613868","article-title":"Daratumumab and blood-compatibility testing","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.01.001_bib96","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy: practical approaches to anti-CD38","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","article-title":"Daratumumab: therapeutic asset, biological trap!","volume":"25","author":"Deneys","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.pathol.2021.01.001_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/vox.12864","article-title":"Risk of RBC alloimmunization in multiple myeloma patients treated by daratumumab","volume":"115","author":"Ye","year":"2020","journal-title":"Vox Sang"},{"key":"10.1016\/j.pathol.2021.01.001_bib99","first-page":"223A","article-title":"Alloimmunization rates and transfusion management of multiple myeloma patients receiving daratumumab-based regimens (P-TS-4)","volume":"60","author":"Phou","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2021.01.001_bib100","series-title":"23rd Congress of the European Hematology Association,","article-title":"Initial phase 1 results of the first-in-class anti-CD47 antibody Hu5F9-G4 in relapsed\/refractory acute myeloid leukemia patients. (PF232)","author":"Vyas","year":"2018"},{"key":"10.1016\/j.pathol.2021.01.001_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21307\/immunohematology-2019-005","article-title":"Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference","volume":"33","author":"Lintel","year":"2017","journal-title":"Immunohematology"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:28:48Z","timestamp":1758472128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302521000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0031302521000428"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.01.001","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of new myeloma agents on the transfusion laboratory","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}